© 2024 Corcept Therapeutics, Incorporated
Pharmacokinetics of the Selective Glucocorticoid Receptor Modulator Miricorilant in Healthy Volunteers and Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Custodio et al. • 2024 • EASL 2024 Congress
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Colombo et al. • 2024 • SGO 2024 Congress
MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
Alkhouri et al. • 2023 • AASLD 2023 Congress
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer
Lorusso et al. • 2023 • IGCS 2023 Congress
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
Donaldson et al. • 2023 • NEALS 22nd Annual Meeting
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Lorusso et al. • 2023 • ESGO 2023 Congress
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
Donaldson et al. • 2023 • ENCALS Meeting 2023